Results 281 to 290 of about 755,388 (347)
Adropin is related to the energy homeostasis‐associated gene. It significantly increased glutathione reductase enzyme levels in the pancreas of experimental diabetic rats. Adropin may reduce the severity of diabetes and its complications. Cell proliferation in the exocrine is reduced after the administration of adropin.
Ifrah I. Ali +4 more
wiley +1 more source
The roles of the small nucleolar RNA host gene family in ovarian cancer. [PDF]
Zhang T +6 more
europepmc +1 more source
Brefeldin A (BFA) significantly inhibits oocyte release and induces apoptosis in ovarian granulosa cells by disrupting follicular development. It downregulates proliferation‐associated genes, reduces SIRT1/SIRT6 proteins, and upregulates cell cycle inhibitors P21 and P16. Additionally, BFA impairs estrogen synthesis and affects ovarian function through
Yao Jiang +8 more
wiley +1 more source
The Expression and Clinical Significance of C1orf106 in Low-Grade Serous Ovarian Cancer. [PDF]
Song F +4 more
europepmc +1 more source
Current radiation medical countermeasures primarily focus on hematopoietic acute radiation syndrome (H‐ARS) using agents like granulocyte colony‐stimulating factor (G‐CSF), granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), and romiplostim, alongside treatments for internal contamination (Prussian blue, diethylenetriamine pentaacetate [DTPA ...
Wen‐Bing Ma +12 more
wiley +1 more source
In this study, we repurposed human Aurora kinase‐specific inhibitors to identify potential antimalarial agents. Two inhibitors, hesperadin and TAE684, exhibited sub‐micromolar activity across multiple parasite stages, with hesperadin demonstrating significant potency and selectivity by specifically targeting PfArk1.
Henrico Langeveld +23 more
wiley +2 more sources
Epidemiology and risk factors for ovarian cancer incidence in the USA: a multilevel analysis. [PDF]
Adekanmbi V +8 more
europepmc +1 more source
Metabolism‐Regulating Nanomedicines for Cancer Therapy
This review highlights metabolism‐regulating nanomedicines designed to target glycolytic, lipid, amino acid, and nucleotide pathways in tumors. By incorporating metabolism‐regulating agents into versatile nanocarriers such as liposomes, micelles, dendrimers, and engineered bacteria, these platforms achieve targeted delivery, controlled release ...
Xiao Wu, Shiyi Geng, Jian Yang
wiley +1 more source

